Health Care Environment Global efforts toward health care cost containment continue to exert pressure on product pricing and market access. In the United States, federal and state governments for many years also have pursued methods to reduce the cost of drugs and vaccines for which they pay. For example, federal laws require the Company to pay specified rebates for medicines reimbursed by Medicaid and to provide discounts for outpatient medicines purchased by certain Public Health Service entities and hospitals serving a disproportionate share of low income or uninsured patients.
Guidelines for examining reference pricing are usually set in local markets and can be changed pursuant to local regulations. In addition, in Japan, the pharmaceutical industry is subject to government-mandated biennial price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order repricings for classes of drugs if it determines that it is appropriate under applicable rules.
Certain markets outside of the United States have also implemented cost management strategies, such as health technology assessments, which require additional data, reviews and administrative processes, all of which increase the complexity, timing and costs of obtaining product reimbursement and exert downward pressure on available reimbursement. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls and related measures, such as compulsory licenses, that aim to put pressure on the price of pharmaceuticals and constrain market access.
The Company anticipates that pricing pressures and market access challenges will continue in to varying degrees in the emerging markets. In addressing cost containment pressures, the Company engages in public policy advocacy with policymakers and continues to work to demonstrate that its medicines provide value to patients and to those who pay for health care.
The Company advocates with government policymakers to encourage a long-term approach to sustainable health care financing that ensures access to innovative medicines and does not disproportionately target pharmaceuticals as a source of budget savings. Operating conditions have become more challenging under the global pressures of competition, industry regulation and cost containment efforts. Company Name, Ticker, Suppliers, else..
More Data on Competitors. List of Competitors by Company. List of Competitors by Segment. See the full list of MRK competitors. All rights reserved. This site uses cookies to make your browsing experince better. All quotes are in local exchange time.
Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Other Ticker:. Merck And Co Inc 's Competitiveness. MRK Sales vs. Those products span different therapeutic areas, including diabetes, oncology, immunology, neuroscience, and more.
Eli Lilly's top-selling drug in FY was Trulicity, which is used to treat type 2 diabetes as well as reduce the risk of significant adverse cardiovascular events. AbbVie is a global biopharmaceutical company based in Chicago. The company's single business segment is engaged in the research and development, manufacturing, commercialization, and sale of innovative medicines and therapies. Its products span a range of healthcare-related areas, including immunology, oncology, aesthetics, neuroscience, eye care, women's health, and more.
AbbVie's top-selling drug in FY was Humira, which is a biologic therapy used to treat a number of autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, adult Crohn's disease, and others. Novartis is a global healthcare company with headquarters in Basel, Switzerland. Its business is organized into two primary divisions: innovative medicines, which develops patent-protected, prescription medications; and Sandoz, which develops generic pharmaceuticals and biosimilars.
The company's focus areas include oncology, immunology, hepatology, dermatology, ophthalmology, neuroscience, cardiovascular, renal, metabolism, and respiratory. Novartis' top-selling drug in FY was Cosentyx, which is an injectable, fully-human, monoclonal antibody used to treat several immunological diseases. Merck is a global healthcare company based in Kenilworth, New Jersey. The company offers prescription medicines, vaccines, biologic therapies, and animal health products.
Its two operating segments are pharmaceutical and animal health. It offers a variety of treatments across a wide range of areas, including oncology, vaccines, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, women's health, livestock products, and companion animal products. Merck's top-selling drug in FY was Keytruda, which is used to treat patients with a range of different types of cancer, such as cervical cancer, classical Hodgkin Lymphoma, certain lung cancers, and numerous others.
Accessed Aug. Roche Holding AG. Eli Lilly and Co. AbbVie Inc. Novartis AG. Company Profiles. Fundamental Analysis. Marijuana Investing. Health Insurance. Tech Stocks. Actively scan device characteristics for identification. Use precise geolocation data. Select personalised content. Create a personalised content profile. Measure ad performance. Select basic ads. Create a personalised ads profile. Select personalised ads. Apply market research to generate audience insights.
Measure content performance. Develop and improve products. List of Partners vendors. Your Money. Personal Finance. Your Practice. Popular Courses. Business Company Profiles.
0コメント